Search

Start Over Subject niacin

1. Poměr přínosů a rizik u přípravků s obsahem niacinu/laropiprantu byl přehodnocen jako negativní

Format:
braille, text, and regular print
Type:
model:article, article, Text, and TEXT
Subject:
lidé, přehodnocení terapeutických indikací léčivého přípravku, hodnocení rizik, systémy pro sběr zpráv o nežádoucích účincích léků, léčivé přípravky, niacin, dyslipidémie--farmakoterapie, statiny, fixní kombinace léků, kyseliny nikotinové, hypolipidemika, Trevaclyn, Pelzont, and Tredaptive
Language:
Czech
Rights:
http://creativecommons.org/publicdomain/mark/1.0/ and policy:public

2. Treatment of hypertriglyceridemia: a review of current options

Creator:
Michal Vrablík and Richard Češka
Format:
print, bez média, and svazek
Type:
article, články, model:article, and TEXT
Subject:
Fyziologie člověka a srovnávací fyziologie, dietní jídla, statiny, omega-3 mastné kyseliny, diet, statins, omega-3 fatty acids, triglycerides, fibrates, ezetimibe, niacin, mipomersen, lomitapide, 14, and 612
Language:
English
Description:
Hypertriglyceridemia is an important marker of increased levels of highly atherogenic rem nant -like particles. The importance of lowering plasma levels of triglycerides (TG) has been called into question many times, but currently it is considered an integral part of residual cardiovascular risk reduction strategies. Lifestyle changes (improved diet and increased physical activity) are effective TG lowering measures. Pharmacological treatment usually starts with statins, although associated TG reductions are typically modest. Fibrates are currently the drugs of choice for hyperTG, frequently in c ombination with statins. Niacin and omega -3 fatty acids improve control of triglyceride levels when the above measures are inadequately effective. Some novel therapies including anti- sense oligonucleotides and inhibitors of microsomal triglyceride transfer protein have shown significant TG lowering efficacy. The current approach to the management of hypertriglyceridemia is based on lifestyle changes and, usually, drug combinations (statin and fibrate and/or omega -3 fatty acids or niacin)., M. Vrablík, R. Češka., and Obsahuje bibliografii
Rights:
http://creativecommons.org/publicdomain/mark/1.0/ and policy:public